Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment

BACKGROUND: Sorafenib is the current standard of care for patients with advanced hepatocellular carcinoma (aHCC) and has been shown to improve survival by about 3 months compared to placebo. However, survival varies widely from under three months to over two years. The aim of this study was to build...

Descripción completa

Detalles Bibliográficos
Autores principales: Berhane, Sarah, Fox, Richard, García-Fiñana, Marta, Cucchetti, Alessandro, Johnson, Philip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738086/
https://www.ncbi.nlm.nih.gov/pubmed/31182766
http://dx.doi.org/10.1038/s41416-019-0488-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738086/
https://www.ncbi.nlm.nih.gov/pubmed/31182766
http://dx.doi.org/10.1038/s41416-019-0488-4

Ejemplares similares